AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.11 +1.71%

+$0.04 today

Market cap
$214.74M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.12M

Average 0.32M

Returns on capital

AC Immune S.A. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-156.8%

avg -31.7%

ROIC

-113.9%

avg -27.0%

ROA

-45.6%

avg -18.1%

Analysis

ROA is currently the strongest return metric at -45.6% versus its period average of -18.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Bojana Portmann

SVP of Intellectual Property,Intellectual Property & Business Development————

Francesca Capotosti

Senior Vice President of Research————

Gary Anthony Waanders

Senior Vice President of Investor Relations & Corporate Communications—62——

Günther Staffler

Executive Vice President of Development—57——

Julien Rongere

Senior Vice President of Regulatory Affairs & Quality Assurance—48——

Martin Zugel

Interim CEO & Chairman of the Board—63——

Matthias Maurer

Senior Vice President & General Counsel—44——

Oliver Sol

Vice President & Head of Clinical Development—59——

Christopher Roberts

Chief Financial Officer & Vice President of Finance—37——

Mark Danton

Executive Vice President of Information Systems & Artificial Intelligence—62——

Piergiorgio Donati

Chief Operating Officer—557.20K<0.01%

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 20, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

3

$90,785.00

Net Transaction Value

−$90,785.00

Net selling

Most Active

Pfeifer Andrea

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 15, 26

Pfeifer Andrea

Direct

Sell$27.9K
Apr 15, 26

Pfeifer Andrea

Direct

Sell$31.4K
Apr 15, 26

Pfeifer Andrea

Direct

Sell$31.4K

Summary

Insiders reported 0 buys worth $0.00 and 3 sells worth $90,785.00 over the last 12 months. That adds up to net selling of $90,785.00. Pfeifer Andrea was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-3.2%
+102.2% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -3.2% over three years. Forward estimates point to Revenue at +102.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does AC Immune S.A. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ACIU's management, answered from reported figures.

Who manages ACIU?

AC Immune S.A. (ACIU) lists 11 active executives. The top listed executive is Bojana Portmann, SVP of Intellectual Property,Intellectual Property & Business Development.

Are ACIU insiders buying or selling?

Recent insider activity shows net buying of $527,828.44.